New torsemide formulation aims to ease bladder symptoms in heart failure
NCT ID NCT06206512
First seen Jan 10, 2026 · Last updated Jun 20, 2026 · Updated 24 times
Summary
This study tested whether an extended-release version of the diuretic torsemide works better than the standard immediate-release form for reducing overactive bladder symptoms in people with chronic heart failure. Twenty-four participants took each version for four weeks, tracking their urinary symptoms and quality of life. The goal was to see if the extended-release form causes fewer bladder problems while still managing fluid buildup.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEART FAILURE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Cardiometabolic Research Unit
Dallas, Texas, 75390, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
torsemide (extended release and immediate release)
What this could lead to
If it works, this could point toward a better-tolerated diuretic that reduces bothersome bladder symptoms in heart failure patients.
What could go wrong
This is a small, early Phase 2 trial with only 24 participants, so results may not apply widely. Torsemide can cause kidney injury, electrolyte loss, and hearing issues.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.